0 Comments

Probiotic strains with documented competitive exclusion effects are live microorganisms shown in particular studies to hinder pathogens or other unwanted microbes by competing for nutrients and attachment sites, producing inhibitory substances, or changing their local environment. Evidence is strongest for specific strains in defined settings—not for probiotics as a whole. Examples include Lactobacillus rhamnosus GG and Lactiplantibacillus plantarum strains in laboratory or food systems, and poultry probiotics such as Enterococcus faecium NCIMB 10415 in studies targeting Salmonella or Campylobacter. The distinction matters: a 2020 Cochrane review found that probiotics probably reduce antibiotic-associated diarrhea in children, but that clinical outcome does not by itself prove competitive exclusion is the mechanism. This article explains how the mechanism is defined, which strains have evidence, how strong that evidence is, and what practical limits apply.

Competitive Exclusion as a Probiotic Strain Attribute

Competitive exclusion is a biological interaction in which one microorganism reduces another organism’s ability to establish, grow, or persist in a shared niche. In probiotic research, the term commonly describes a proposed protective effect against pathogens. The concept is related to, but not identical with, pathogen killing: a strain can exclude a pathogen by occupying a binding site or consuming a limiting nutrient without directly killing it.

The World Health Organization and Food and Agriculture Organization define probiotics as “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.” That definition sets a higher bar than simply finding a microbe that inhibits another in a dish. A probiotic claim should identify the strain, dose, host or product context, and demonstrated benefit. The International Scientific Association for Probiotics and Prebiotics likewise emphasizes that probiotic effects are strain-specific and evidence-specific.

Competitive exclusion is usually discussed through several overlapping mechanisms: competition for nutrients and attachment sites, production of antimicrobial compounds, and modification of conditions such as pH. Researchers may also measure downstream outcomes—such as reduced pathogen counts or lower infection rates—but those outcomes alone cannot establish which mechanism caused the effect.

Nutrient and attachment-site competition

Nutrient competition occurs when a probiotic consumes resources that a pathogen also needs. Attachment-site competition occurs when probiotic cells or their surface molecules occupy epithelial or food-surface binding sites, limiting pathogen access. These effects are highly dependent on the particular strain, the target pathogen, and the environment; an in-vitro adhesion result does not guarantee colonization or protection in a person or animal.

Antimicrobial production and environmental change

Some lactic acid bacteria produce organic acids, hydrogen peroxide, or bacteriocins—ribosomally produced antimicrobial peptides—that can suppress susceptible competitors. Acidification can inhibit growth of some pathogens, while bacteriocins may act more selectively. These products can contribute to exclusion, but activity demonstrated in laboratory media may be reduced by food composition, digestive conditions, or dilution in a host.

How evidence is validated

Evidence ranges from laboratory inhibition assays and animal challenge studies to controlled human trials. A useful hierarchy asks whether the study identifies the strain, tests the relevant pathogen, measures a meaningful outcome, and reproduces the result under realistic conditions. A clinical effect should not be labeled competitive exclusion unless the mechanism itself has been tested; otherwise, it is more accurate to say that the probiotic was associated with a protective outcome.

Documented Probiotic Strain Groups and Their Competitive Effects

The examples below illustrate different kinds of evidence rather than a universal ranking. Probiotic nomenclature has changed in recent years: for example, many organisms historically called Lactobacillus have been reassigned to new genera. Strain identifiers are therefore important for finding and interpreting studies.

Lactic acid bacteria: Lactobacillus and related genera

Lactic acid bacteria are among the most frequently studied organisms for pathogen inhibition. Lacticaseibacillus rhamnosus GG, formerly Lactobacillus rhamnosus GG, has been examined for adhesion, pathogen interaction, and intestinal effects. Laboratory studies report that it can interfere with the adhesion of some pathogens and produce inhibitory compounds, but those findings should not be generalized to all L. rhamnosus strains or treated as proof that the strain prevents every infection.

Lactiplantibacillus plantarum strains, including strains used in fermented foods and experimental preparations, have also shown competitive or inhibitory effects against organisms such as Salmonella and Escherichia coli in selected in-vitro and animal models. Their effects may involve acidification, bacteriocins, and competition for attachment. The specific strain and experimental setting determine whether these mechanisms translate into a measurable benefit.

Human evidence is outcome-specific. The Cochrane review by Guo and colleagues, published in 2020, included 33 studies involving 6,352 children and found that probiotics probably reduced antibiotic-associated diarrhea, with the review reporting diarrhea in 8% of probiotic recipients versus 19% of controls across the studies contributing to that comparison. The review assessed clinical outcomes across probiotic products; it did not establish that competitive exclusion was the mechanism or that every included strain would produce the same result.

Poultry competitive-exclusion cultures

In poultry, competitive-exclusion products are microbial preparations administered to young birds to help establish a protective intestinal community before pathogens gain a foothold. The approach developed from observations that mature birds are generally less susceptible to intestinal colonization by Salmonella than newly hatched chicks. Some preparations contain multiple bacterial species rather than a single probiotic strain, so their effects cannot automatically be attributed to one organism.

Studies and regulatory evaluations have examined defined products such as Enterococcus faecium NCIMB 10415 and multispecies cultures for effects on poultry gut ecology and pathogen shedding. The European Food Safety Authority has assessed this strain as a feed additive in animal production, while research on competitive-exclusion cultures has reported reduced pathogen colonization under specific challenge conditions. Results depend on dose, timing, bird age, farm hygiene, and the challenge protocol; a culture is not a substitute for biosecurity or food-safety controls.

Bifidobacteria and intestinal niche competition

Bifidobacterium species are common members of the human intestinal microbiota and are included in some probiotic products. Selected strains have shown pathogen-inhibitory effects in laboratory studies, including competition for nutrients and production of organic acids. However, the genus name alone does not identify a proven competitive-exclusion effect: results for one strain cannot be assumed for another, and laboratory inhibition does not establish clinical prevention.

Food-fermentation strains and pathogen control

Starter cultures used in fermented foods can suppress unwanted organisms through acid production, nutrient use, and bacteriocins. Certain Lactococcus and Lactiplantibacillus strains are studied for control of foodborne bacteria in particular products. In this context, competitive exclusion is a food-microbiology tool: its success depends on the recipe, temperature, storage time, and pathogen, and it should complement validated processing and sanitation practices rather than replace them.

What the Evidence Does—and Does Not—Show

A documented effect is narrower than a broad claim that “probiotics block pathogens.” Studies support particular strain–target–setting combinations. A strain may inhibit a pathogen in a culture plate but fail to establish in the gut; a reduction in pathogen counts in animals may not predict a reduction in human illness. Conversely, a clinical benefit can occur through immune, metabolic, or barrier effects without competitive exclusion being the primary explanation.

The U.S. National Center for Complementary and Integrative Health notes that evidence for probiotics varies by condition and that many products have not been studied for specific uses. Product labels also matter: species and strain identity, viable count through the end of shelf life, storage requirements, and intended population can all influence whether study findings apply to a commercial product.

A practical checklist for evaluating a strain

  • Confirm the full strain designation, not just the species name.
  • Identify the target pathogen, host, route of administration, dose, and duration studied.
  • Separate direct mechanism evidence from clinical or production outcomes.
  • Look for replicated, controlled studies and outcomes relevant to the intended use.
  • Check safety information and whether the product is appropriate for the intended population.

Applications, Limitations, and Safety

Competitive exclusion has practical applications in animal production, food fermentation, and research into intestinal health. In poultry, early microbial establishment may help reduce pathogen colonization; in food processing, starter cultures can support microbial stability; and in clinical settings, selected probiotic products may be considered for specific indications. These are distinct applications, and evidence from one should not be transferred automatically to another.

Probiotics are generally well tolerated by many healthy people, but they are not risk-free for everyone. The U.S. National Center for Complementary and Integrative Health cautions that serious adverse effects, although uncommon, may be more likely in people with severe illness or weakened immune systems. People considering probiotics for a medical condition—especially those who are immunocompromised, critically ill, or caring for a premature infant—should seek advice from a qualified health professional.

For food safety and animal production, probiotics should be used within a broader control plan. Sanitation, vaccination where appropriate, sound husbandry, validated processing, and monitoring remain essential. Competitive exclusion may reduce risk, but it does not guarantee pathogen elimination.

Conclusion: Strain-Specific Evidence Is the Key Attribute

Competitive exclusion describes how a microorganism can limit a competitor through niche occupation, resource use, antimicrobial production, or environmental change. Research has documented such effects for selected lactic acid bacteria, bifidobacteria, poultry cultures, and food-fermentation strains, but the evidence is specific to the strain, pathogen, and setting. Clinical outcomes such as reduced antibiotic-associated diarrhea are valuable, yet they do not prove that competitive exclusion caused the benefit.

The most useful next step for readers, clinicians, food producers, and animal-health professionals is to evaluate the exact strain and the evidence for the intended application. Further reading should prioritize systematic reviews, regulatory assessments, and controlled studies that report strain identifiers, viable doses, safety, and meaningful outcomes.

Sources: Hill C, Guarner F, Reid G, et al., “The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic,” Nature Reviews Gastroenterology & Hepatology, 2014, https://www.nature.com/articles/nrgastro.2014.66; World Health Organization and Food and Agriculture Organization of the United Nations, “Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation,” 2006, https://www.fao.org/4/a0512e/a0512e.pdf; Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC, “Probiotics for the prevention of pediatric antibiotic-associated diarrhea,” Cochrane Database of Systematic Reviews, 2020, https://doi.org/10.1002/14651858.CD004827.pub5; U.S. National Center for Complementary and Integrative Health, “Probiotics: What You Need To Know,” https://www.nccih.nih.gov/health/probiotics-what-you-need-to-know; European Food Safety Authority, “Safety and efficacy of a feed additive consisting of Enterococcus faecium NCIMB 10415 for chickens for fattening,” EFSA Journal, https://efsa.onlinelibrary.wiley.com/; FAO and WHO, “Guidelines for the Evaluation of Probiotics in Food,” 2002, https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts